Nimbus Therapeutics: $2B valuation, IPO Readiness 57, Series D. Structure-based drug design company using computational tools to develop precision medicines. Track live on The IPO Stack.
Structure-based drug design company using computational tools to develop precision medicines.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Nimbus Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Nimbus Therapeutics has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Nimbus Therapeutics is valued at $2B as of November 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Nimbus Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Nimbus Therapeutics scores 57/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Nimbus Therapeutics has raised $475M in total venture capital and private equity funding, with backing from Andreessen Horowitz Bio, Atlas Venture, Andreessen Horowitz.
Nimbus Therapeutics's notable investors include Andreessen Horowitz Bio, Atlas Venture, Andreessen Horowitz, Bill & Melinda Gates Foundation. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Nimbus Therapeutics is a Biotechnology company. Structure-based drug design company using computational tools to develop precision medicines.